Jae Kim1,2, Shailesh Male1,2, Bharathi D Jagadeesan1,2, Christopher Streib1, Ramachandra P Tummala3,4. 1. Department of Neurology, University of Minnesota Medical School and Hennepin County Medical Center, Minneapolis, MN, USA. 2. Department of Neurosurgery, University of Minnesota Medical School and Hennepin County Medical Center, MMC 96, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. 3. Department of Neurology, University of Minnesota Medical School and Hennepin County Medical Center, Minneapolis, MN, USA. tumm0011@umn.edu. 4. Department of Neurosurgery, University of Minnesota Medical School and Hennepin County Medical Center, MMC 96, 420 Delaware St. SE, Minneapolis, MN, 55455, USA. tumm0011@umn.edu.
Abstract
PURPOSE: Contrast-induced nephropathy is a common clinical concern in patients undergoing neuroendovascular procedures, especially in those with pre-existent kidney disease. We aimed to define the incidence of contrast-induced nephropathy in these high-risk patients in our practice. METHODS: We analyzed data retrospectively from patients undergoing neuroendovascular procedures at two academic medical centers over a 4-year period. Contrast-induced nephropathy was determined by an absolute increase in serum creatinine of 0.5 mg/dL or a rise from its baseline value by ≥ 25%, at 48-72 h after exposure to contrast agent after excluding other causes of renal impairment. High-risk patients were identified as those with pre-procedural estimated glomerular filtration rate < 60 mL/min irrespective of creatinine level, corresponding to stages 3-5 of chronic kidney disease. RESULTS: One hundred eighty-five high-risk patients undergoing conventional cerebral angiography and neuroendovascular interventions were identified. Only 1 out of 184 (0.54%) high-risk patients developed contrast-induced nephropathy. That one patient had stage 5 chronic kidney disease and multiple other risk factors. CONCLUSION: We have observed a very low rate of renal injury in patients with chronic kidney disease, traditionally considered high risk for neuroendovascular procedures. Multiple factors may be responsible in the risk reduction of contrast-induced nephropathy in this patient population.
PURPOSE: Contrast-induced nephropathy is a common clinical concern in patients undergoing neuroendovascular procedures, especially in those with pre-existent kidney disease. We aimed to define the incidence of contrast-induced nephropathy in these high-risk patients in our practice. METHODS: We analyzed data retrospectively from patients undergoing neuroendovascular procedures at two academic medical centers over a 4-year period. Contrast-induced nephropathy was determined by an absolute increase in serum creatinine of 0.5 mg/dL or a rise from its baseline value by ≥ 25%, at 48-72 h after exposure to contrast agent after excluding other causes of renal impairment. High-risk patients were identified as those with pre-procedural estimated glomerular filtration rate < 60 mL/min irrespective of creatinine level, corresponding to stages 3-5 of chronic kidney disease. RESULTS: One hundred eighty-five high-risk patients undergoing conventional cerebral angiography and neuroendovascular interventions were identified. Only 1 out of 184 (0.54%) high-risk patients developed contrast-induced nephropathy. That one patient had stage 5 chronic kidney disease and multiple other risk factors. CONCLUSION: We have observed a very low rate of renal injury in patients with chronic kidney disease, traditionally considered high risk for neuroendovascular procedures. Multiple factors may be responsible in the risk reduction of contrast-induced nephropathy in this patient population.
Authors: Richard J Solomon; Madhu K Natarajan; Serge Doucet; Samin K Sharma; Cezar S Staniloae; Richard E Katholi; Joseph L Gelormini; Marino Labinaz; Abel E Moreyra Journal: Circulation Date: 2007-06-11 Impact factor: 29.690
Authors: Gregory E Tong; Sant Kumar; Karen C Chong; Nikita Shah; Margaret J Wong; Jeffrey M Zimmet; Zhen Jane Wang; Judy Yee; Yanjun Fu; Benjamin M Yeh Journal: Abdom Radiol (NY) Date: 2016-01